Y Intercept Hong Kong Ltd Boosts Holdings in GE HealthCare Technologies Inc. $GEHC

Y Intercept Hong Kong Ltd lifted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 707.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,056 shares of the company’s stock after purchasing an additional 108,695 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in GE HealthCare Technologies were worth $10,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Wealthspire Advisors LLC raised its position in shares of GE HealthCare Technologies by 48.8% in the 4th quarter. Wealthspire Advisors LLC now owns 9,851 shares of the company’s stock worth $808,000 after purchasing an additional 3,230 shares during the last quarter. Macquarie Group Ltd. raised its position in shares of GE HealthCare Technologies by 16.7% in the 4th quarter. Macquarie Group Ltd. now owns 90,681 shares of the company’s stock worth $7,437,000 after purchasing an additional 12,974 shares during the last quarter. Quadrant Capital Group LLC raised its position in shares of GE HealthCare Technologies by 1.1% in the 4th quarter. Quadrant Capital Group LLC now owns 12,557 shares of the company’s stock worth $1,030,000 after purchasing an additional 140 shares during the last quarter. Federation des caisses Desjardins du Quebec raised its position in shares of GE HealthCare Technologies by 37.5% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 56,614 shares of the company’s stock worth $4,644,000 after purchasing an additional 15,452 shares during the last quarter. Finally, DRW Securities LLC purchased a new position in shares of GE HealthCare Technologies in the 4th quarter worth about $238,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research report on Thursday, April 30th. Barclays lowered their price target on GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating for the company in a research report on Thursday, April 30th. Citigroup lowered their price target on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research report on Thursday, April 30th. BNP Paribas Exane reduced their price objective on GE HealthCare Technologies from $95.00 to $88.00 in a report on Friday, May 1st. Finally, BTIG Research reduced their price objective on GE HealthCare Technologies from $85.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Nine investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, GE HealthCare Technologies has an average rating of “Moderate Buy” and a consensus price target of $80.21.

Insider Buying and Selling

In other GE HealthCare Technologies news, Director Kevin Lobo acquired 10,000 shares of GE HealthCare Technologies stock in a transaction that occurred on Friday, May 22nd. The stock was bought at an average cost of $64.18 per share, for a total transaction of $641,800.00. Following the acquisition, the director owned 14,363 shares of the company’s stock, valued at $921,817.34. This represents a 229.20% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Peter J. Arduini purchased 4,169 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were purchased at an average price of $59.92 per share, with a total value of $249,806.48. Following the completion of the purchase, the chief executive officer owned 259,424 shares in the company, valued at approximately $15,544,686.08. This trade represents a 1.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 21,847 shares of company stock worth $1,361,355 in the last three months. 0.36% of the stock is currently owned by company insiders.

GE HealthCare Technologies Price Performance

NASDAQ GEHC opened at $65.18 on Friday. GE HealthCare Technologies Inc. has a one year low of $58.75 and a one year high of $89.77. The stock has a 50-day moving average of $66.32 and a 200 day moving average of $75.20. The company has a market capitalization of $29.65 billion, a price-to-earnings ratio of 15.59, a PEG ratio of 1.45 and a beta of 0.74. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.95 and a current ratio of 1.22.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.07 by ($0.08). GE HealthCare Technologies had a return on equity of 20.46% and a net margin of 9.10%.The business had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same quarter in the previous year, the business posted $1.01 earnings per share. GE HealthCare Technologies’s quarterly revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. On average, sell-side analysts forecast that GE HealthCare Technologies Inc. will post 4.89 EPS for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.